Did you finish first line chemo for stage 3 or ... - My Ovacome

My Ovacome

17,746 members19,983 posts

Did you finish first line chemo for stage 3 or 4 ovarian, fallopian tube or primary peritoneal cancer between 22 August 2021 - 22 June 2022

OvacomeSupport profile image
OvacomeSupportPartnerMy Ovacome Team
2 Replies

Good afternoon everyone

Have you been diagnosed with stage 3 or 4 ovarian, primary peritoneal or fallopian tube cancer and did you have your last dose of first line chemotherapy sometime between 22 August 2021 and 22 June 2022?

If so, you may be eligible to take part in an important new study which aims to identify areas for improvement in supporting the lives of patients at different stages of their treatment pathway and to contribute to the mutual understanding between patients and their consultants, nurses and surgeons.

As well as looking at the emotional and physical effects felt by patients after treatment, it will investigate whether clinicians understand these challenges and how they might be supported to address the clinical and emotional needs of those they treat.

This study involves completing a survey. This is non-interventional observational study, meaning that participants will not receive any treatment as part of the study.

All study participants will receive £50 on successful completion of the survey.

Here is some further information about criteria for participation:

• You must have received treatment in the UK.

• You must be over 18.

• You must have been diagnosed with epithelial ovarian cancer (high grade serous, low grade serous, endometrioid, clear cell, mucinous), fallopian tube cancer, or primary peritoneal cancer.

• You must have been diagnosed at stage 3 or 4.

• As first line treatment you must have had either:

• Chemotherapy only

• Surgery and then chemotherapy

• Chemotherapy, followed by surgery, followed by more chemotherapy

• You must have finished your first line chemotherapy treatment between two and 12 months prior to taking part in the survey.

If you would like to know more about this study, please visit ovacome.org.uk/news/patron. You can also contact the Ovacome support team on 0800 008 7054 or by emailing support@ovacome.org.uk.

If you would like to participate in this study please call: 01625 668988.

Please don’t hesitate to get in touch if we can help with any further information or if there is anything we can do to support your participation.

Best wishes

Annie - Ovacome support

Written by
OvacomeSupport profile image
OvacomeSupport
Partner
To view profiles and participate in discussions please or .
Read more about...
2 Replies
Dubai18 profile image
Dubai18

Hi Annie, I was diagnosed with HG stge 4, spread to peritoneum, and lymph nodes Ovarian Cancer, primary in right ovary. Can I help?

OvacomeSupport profile image
OvacomeSupportPartnerMy Ovacome Team in reply to Dubai18

Hello Dubai18,

Thank you very much for your message about the PATRON study. This study is open for anyone who has been diagnosed with stage 3 or 4 ovarian, primary peritoneal or fallopian tube cancer and who finished first line chemotherapy treatment between two and 12 months prior to taking part in the survey, this would be between 22 August 2021 and 22 June 2022.

There are some other eligibility criteria too which are listed in the message above. If you would like to participate and feel that you may be eligible, please contact 01625 668988.

We would be very happy to discuss this with you if you would like. If you would like to talk things through or if you have any questions about the study, you can contact us by calling 0800 008 7054 or by emailing support@ovacome.org.uk.

Many thanks again for contacting us about this.

Best wishes,

Cathryn

Ovacome Support

You may also like...

NICE review of first-line olaparib - your comments needed

for maintenance treatment of BRCA-mutated ovarian, fallopian tube and peritoneal cancer after...

Rucaparib - your experiences needed

maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer...

NICE review olaparib and bevacizumab - your comments needed

treatment plan for ovarian, fallopian tube or peritoneal cancer or if you have received this in the...

Niraparib - NICE appraisal

recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to...

Rucaparib submission to NICE

maintenance treatment of recurrent platinum-sensitive epithelial ovarian, fallopian tube and...